You Position: Home > Paper
Immune function analysis after interferon treatment in post-surgery patients with localized clear cell renal cell carcinoma
( views:385, downloads:0 )
- Author:
- No author available
- Journal Title:
- Academic Journal of Second Military Medical University
- Issue:
- 9
- DOI:
- 10.3724/SP.J.1008.2012.01028
- Key Word:
- 肾肿瘤;免疫疗法;干扰素α-2b;免疫功能
Abstract： 目的 评价干扰素辅助治疗对局限性肾透明细胞癌患者术后免疫指标的影响及其临床意义.方法 对35例局限性肾透明细胞癌患者术后应用干扰素α-2b进行免疫辅助治疗,6 MIU/次,每周3次,共持续3个月.免疫治疗前以及治疗开始后第1、2、4、8、16周抽取外周血,检测细胞免疫相关指标CD4+、CD8+、CD4+/CD8+、CD16+ 56+、CD19+和体液免疫相关指标IL-2、IL 6、IL-10、IL-8、TNF-α,比较各免疫指标手术前后的变化.结果 免疫治疗3个月疗程结束后,患者细胞免疫指标CD4+、CD8+、CD4+/CD8+与治疗前比较差异无统计学意义；CD16+ 56+在治疗开始后前两周升高,第2周时与治疗前比较差异有统计学意义(P＜0.05),但在第16周时较治疗前下降(P＜0.01)；CD19+在治疗开始后第1、2、4周较治疗前降低(P均＜0.01),但在第16周时较治疗前升高(P＜0.01).体液免疫各项指标中,IL-8水平在治疗开始后第4周时较治疗前降低(P＜0.05),TNF-α在治疗开始后第8周时较治疗前升高(P＜0.01).治疗结束后,即第16周时,所有体液免疫指标与治疗前比较差异均无统计学意义.结论 局限性肾透明细胞癌术后应用干扰素免疫辅助治疗(6 MIU/次,每周3次,共持续3个月)对于提高患者部分免疫指标水平效果不明显,此免疫治疗方案对患者远期生存期的影响需要进一步随访观察.
- [1]马建辉,鲍镇美.干扰素治疗肾癌[J].2003,(6).
- [2]朱伟,付杰新,李建安,等.α-干扰素在肾癌根治术后的治疗作用[J].2001,(6).
- [3]Sandock DS,Seftel AD,Resnick MI.A new protocol for the followup of renal cell carcinoma based on pathological stage.[J].1995,154(1).
- [4]Escudier B,Bajetta E,Ravaud A,etc.Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.[J].2007,370(9605).
- [5]Piva L,Pizzocaro G,Colavita M,etc.Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study.[J].2001,19(2).
- [6]Bennedsgaard KM,Marcussen N,Fisker R,etc.Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.[J].2002,87(2).
- [7]Pardoll DM,Weiner GJ,Topalian SL.Cancer immunotherapy comes of age.[J].2011,29(36).
- [8]Trump D,Pontes JE,Messing EM,etc.Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial.[J].2003,21(7).
- [9]Marino CB,Miller EK,Gollob JA,etc.Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.[J].2007,25(22).
- [10]Ljungberg,B.,Cowan,N.C.,Hanbury,D.C.,etc.EAU guidelines on renal cell carcinoma: The 2010 update[J].2010,58(3).
- [11]R A, Rabinovitch,M J, Zelefsky,J J, Gaynor,etc.Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy.[J].1994,12.
- [12]C, Coppin,F, Porzsolt,A, Awa,etc.Immunotherapy for advanced renal cell cancer.[J].2005,(1).
- [13]Vaena DA,Small EJ,Archer L,etc.Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.[J].2010,28(13).
- [14]Pan CX,Ryan CW,Drabkin HA,etc.Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.[J].2007,25(22).
- [15]S, St?rkel,J N, Eble,K, Adlakha,etc.Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC).[J].1997,80.